

Peter P De Deyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3462407/publications.pdf>

Version: 2024-02-01

258
papers

19,670
citations

36203

51
h-index

13727

129
g-index

303
all docs

303
docs citations

303
times ranked

21904
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal dynamics of depression, cognitive performance and sleep in older persons with depressive symptoms and cognitive impairments: a series of eight single-subject studies. <i>International Psychogeriatrics</i> , 2022, 34, 47-59.	0.6	8
2	The neglected puzzle of dementia in people with severe/profound intellectual disabilities: A systematic literature review of observable symptoms. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2022, 35, 24-45.	1.3	14
3	Short- and Long-Term Functional Connectivity Differences Associated with Alzheimer's Disease Progression. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2022, 11, 235-249.	0.6	8
4	Age-related cognitive decline in spatial learning and memory of C57BL/6J mice. <i>Behavioural Brain Research</i> , 2022, 418, 113649.	1.2	14
5	Planning in amnesic mild cognitive impairment: an fMRI study. <i>Experimental Gerontology</i> , 2022, 159, 111673.	1.2	1
6	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. <i>Brain</i> , 2022, 145, 4056-4064.	3.7	19
7	Plasma 5-HIAA activity indicative of serotonergic disturbances in cognitively impaired, elderly patients experiencing postoperative delirium. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	1
8	Validation and test-retest repeatability performance of parametric methods for [¹¹ C]UCB-J PET. <i>EJNMMI Research</i> , 2022, 12, 3.	1.1	3
9	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. <i>Toxicology Letters</i> , 2022, 356, 89-99.	0.4	8
10	Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2738.	1.8	1
11	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
12	A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies. <i>Frontiers in Psychiatry</i> , 2022, 13, 879491.	1.3	15
13	Dementia in People with Severe/Profound Intellectual (and Multiple) Disabilities: Practice-Based Observations of Symptoms. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2022, 15, 364-393.	1.3	1
14	Safety, pharmacokinetics and target engagement of novel <i>RIPK1</i> inhibitor <i>SAR443060</i> (<i>DNL747</i>) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/II studies in healthy subjects and patients. <i>Clinical and Translational Science</i> , 2022, 15, 2010-2023.	1.5	31
15	Alzheimer's disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA. <i>EJNMMI Research</i> , 2022, 12, .	1.1	4
16	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. <i>Neurobiology of Aging</i> , 2021, 97, 145.e1-145.e4.	1.5	2
17	Kinetics and 28-day test-retest repeatability and reproducibility of [¹¹ C]UCB-J PET brain imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1338-1350.	2.4	14
18	Widespread white matter aberration is associated with the severity of apathy in amnesic Mild Cognitive Impairment: Tract-based spatial statistics analysis. <i>NeuroImage: Clinical</i> , 2021, 29, 102567.	1.4	14

#	ARTICLE	IF	CITATIONS
19	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102712.	1.4	42
20	Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. <i>NeuroImage: Clinical</i> , 2021, 30, 102625.	1.4	4
21	Coronary Artery Calcium and Cognitive Function in Dutch Adults: Cross-sectional Results of the Population-Based ImaLife Study. <i>Journal of the American Heart Association</i> , 2021, 10, e018172.	1.6	5
22	Amyloid burden quantification depends on PET and MR image processing methodology. <i>PLoS ONE</i> , 2021, 16, e0248122.	1.1	5
23	The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research. <i>Annals of Translational Medicine</i> , 2021, 9, 455-455.	0.7	7
24	Functional connectivity differences in Alzheimer's disease and amnesic mild cognitive impairment associated with AT(N) classification and anosognosia. <i>Neurobiology of Aging</i> , 2021, 101, 22-39.	1.5	15
25	PET Agents in Dementia: An Overview. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 196-229.	2.5	23
26	Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6656.	1.8	11
27	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation ¹ . <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1505-1527.	1.2	14
28	Dementia in people with severe or profound intellectual (and multiple) disabilities: Focus group research into relevance, symptoms and training needs. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2021, 34, 1602-1617.	1.3	10
29	How well do people living with neurodegenerative diseases manage their finances? A meta-analysis and systematic review on the capacity to make financial decisions in people living with neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 709-739.	2.9	14
30	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 104, 105.e1-105.e6.	1.5	8
31	Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases. <i>Ageing Research Reviews</i> , 2021, 70, 101414.	5.0	39
32	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 623-639.	1.2	7
33	Altered stress hormone levels affect in vivo vascular function in the hAPP23 [±] overexpressing mouse model of Alzheimer's disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 321, H905-H919.	1.5	2
34	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.	2.4	6
35	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. <i>Neurobiology of Aging</i> , 2021, 106, 307.e1-307.e7.	1.5	10
36	Pain processing in older adults with dementia-related cognitive impairment is associated with frontal neurodegeneration. <i>Neurobiology of Aging</i> , 2021, 106, 139-152.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Chronic adolescent stress increases exploratory behavior but does not appear to change the acute stress response in adult male C57BL/6 mice. <i>Neurobiology of Stress</i> , 2021, 15, 100388.	1.9	3
38	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 1-10.	1.5	12
39	5-HT7 receptors in Alzheimer's disease. <i>Neurochemistry International</i> , 2021, 150, 105185.	1.9	12
40	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 108, 99-109.	1.5	13
41	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
42	Levels of circulating memory CD8 T cells that induce AD-like pathology in mice correlate with cognition and decreased CSF A β 1-42 in AD and control patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Neural correlates of executive functions in people with amnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImLife (Imaging in Lifelines) Study. <i>European Journal of Epidemiology</i> , 2020, 35, 75-86.	2.5	32
45	The retinal nerve fiber layer as a window to the glymphatic system. <i>Clinical Neurology and Neurosurgery</i> , 2020, 188, 105593.	0.6	1
46	Pentylentetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of Tauopathy. <i>Neuroscience</i> , 2020, 425, 112-122.	1.1	12
47	Iron chelators inhibit amyloid- β 2-induced production of lipocalin 2 in cultured astrocytes. <i>Neurochemistry International</i> , 2020, 132, 104607.	1.9	17
48	Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice. <i>Neurobiology of Disease</i> , 2020, 143, 105011.	2.1	9
49	Uptake and effectiveness of a tailor-made online lifestyle programme targeting modifiable risk factors for dementia among middle-aged descendants of people with recently diagnosed dementia: study protocol of a cluster randomised controlled trial (Demin study). <i>BMJ Open</i> , 2020, 10, e039439.	0.8	3
50	The Possible Role of Elastic Properties of the Brain and Optic Nerve Sheath in the Development of Spaceflight-Associated Neuro-Ocular Syndrome. <i>American Journal of Neuroradiology</i> , 2020, 41, E14-E15.	1.2	10
51	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. <i>Acta Neurologica Belgica</i> , 2020, 120, 1157-1163.	0.5	3
52	Recessive missense variants in VWA2 increase risk of developing Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039791.	0.4	0
53	ABCA7 mutations are major contributors to Alzheimer's disease in Belgian patients. <i>Alzheimer's and Dementia</i> , 2020, 16, e040227.	0.4	0
54	Apathy and white matter integrity in amnesic mild cognitive impairment: A whole brain analysis with tract-based spatial statistics. <i>Alzheimer's and Dementia</i> , 2020, 16, e040838.	0.4	0

#	ARTICLE	IF	CITATIONS
55	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041513.	0.4	0
56	Knowledge, beliefs and attitudes towards dementia risk assessment and reduction among individuals with a parental family history of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e042533.	0.4	0
57	Demin: Design and baseline results of a cluster randomized controlled trial investigating the uptake and effectiveness of a dementia risk reduction program in middle-aged descendants of people with recently diagnosed Alzheimer disease or vascular dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e042609.	0.4	0
58	A family-based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. <i>Alzheimer's and Dementia</i> , 2020, 16, e047212.	0.4	2
59	Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. <i>Neurochemical Research</i> , 2020, 45, 1191-1201.	1.6	12
60	A complete pupillometry toolbox for real-time monitoring of locus coeruleus activity in rodents. <i>Nature Protocols</i> , 2020, 15, 2301-2320.	5.5	46
61	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 735-744.	0.6	33
62	The Relationship of Coronary Artery Calcium and Clinical Coronary Artery Disease with Cognitive Function: A Systematic Review and Meta-Analysis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 934-958.	0.9	13
63	Functional network topology associated with apathy in Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2020, 266, 473-481.	2.0	15
64	Bioethical implications of end-of-life decision-making in patients with dementia: a tale of two societies. <i>Monash Bioethics Review</i> , 2020, 38, 49-67.	0.4	6
65	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 768-788.	1.7	32
66	Alzheimer's disease: Neurotransmitters of the sleep-wake cycle. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 105, 72-80.	2.9	29
67	Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2019, 151, 656-668.	2.1	81
68	Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer's disease. <i>EJNMMI Research</i> , 2019, 9, 59.	1.1	19
69	Sleep architecture changes in the APP23 mouse model manifest at onset of cognitive deficits. <i>Behavioural Brain Research</i> , 2019, 373, 112089.	1.2	18
70	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	0.5	9
71	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. <i>Neuron</i> , 2019, 103, 702-718.e5.	3.8	198
72	Clinical Considerations in Physician-Assisted Death for Probable Alzheimer's Disease: Decision-Making Capacity, Anosognosia, and Suffering. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 217-226.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Inducing Physical Inactivity in Mice: Preventing Climbing and Reducing Cage Size Negatively Affect Physical Fitness and Body Composition. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 221.	1.0	17
74	Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimer's disease. <i>Medical Hypotheses</i> , 2019, 122, 57.	0.8	0
75	Alzheimer's disease and glaucoma: Look-alike neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2019, 15, 600-601.	0.4	7
76	Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies. <i>PLoS ONE</i> , 2019, 14, e0211000.	1.1	33
77	Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 49.	1.4	49
78	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 989-1001.	1.2	14
79	Functional Neural Correlates of Anosognosia in Mild Cognitive Impairment and Alzheimer's Disease: a Systematic Review. <i>Neuropsychology Review</i> , 2019, 29, 139-165.	2.5	41
80	Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. <i>Vascular Pharmacology</i> , 2019, 118-119, 106561.	1.0	14
81	Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1019-1030.	1.2	15
82	Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient. <i>Neurochemistry International</i> , 2019, 128, 154-162.	1.9	14
83	PTZ-induced seizures in mice require a revised Racine scale. <i>Epilepsy and Behavior</i> , 2019, 95, 51-55.	0.9	129
84	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1151-1159.	1.2	9
85	Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2019, 320, 128-137.	1.3	6
86	The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy. <i>PLoS ONE</i> , 2019, 14, e0210567.	1.1	6
87	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
88	Optimization of the k $_{2}$ Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2. <i>Frontiers in Physics</i> , 2019, 7, .	1.0	7
89	P1291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P355.	0.4	0
90	Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. <i>Vascular Pharmacology</i> , 2019, 113, 70-76.	1.0	24

#	ARTICLE	IF	CITATIONS
91	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. <i>Neurobiology of Aging</i> , 2018, 67, 84-94.	1.5	17
92	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 31.	3.0	42
93	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	1.5	12
94	Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?. <i>Medical Hypotheses</i> , 2018, 118, 174.	0.8	1
95	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018, 135, 827-837.	3.9	68
96	Fibromyalgia as a glymphatic overload syndrome. <i>Medical Hypotheses</i> , 2018, 115, 17-18.	0.8	4
97	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 172-181.	1.2	16
98	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	1.5	19
99	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
100	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	1.5	16
101	Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus. <i>Sleep Medicine Reviews</i> , 2018, 40, 17-27.	3.8	71
102	O4â€1â€1: INâ€DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1400.	0.4	0
103	P3â€128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1116.	0.4	0
104	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 373-381.	1.2	12
105	Episodic memory in mild cognitive impairment inversely correlates with the global modularity of the cerebral blood flow network. <i>Psychiatry Research - Neuroimaging</i> , 2018, 282, 73-81.	0.9	7
106	P3â€307: THE ASSOCIATION BETWEEN APATHY AND STRUCTURAL BRAIN ALTERATIONS IN AMNESTIC MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1199.	0.4	0
107	Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model. <i>Journal of Neuroinflammation</i> , 2018, 15, 330.	3.1	45
108	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. <i>Neurobiology of Aging</i> , 2018, 69, 292.e7-292.e14.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. Medical Hypotheses, 2018, 118, 98-102.	0.8	11
110	Lower Choline and Myo-Inositol in Temporo-Parietal Cortex Is Associated With Apathy in Amnesic MCI. Frontiers in Aging Neuroscience, 2018, 10, 106.	1.7	18
111	The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy. Medical Hypotheses, 2018, 118, 142-145.	0.8	16
112	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease, 2018, 63, 797-819.	1.2	38
113	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
114	Crossed Cerebellar Diaschisis in Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 1267-1275.	0.7	13
115	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiology of Aging, 2017, 51, 177.e9-177.e16.	1.5	60
116	Glymphatic stasis at the site of the lamina cribrosa as a potential mechanism underlying open-angle glaucoma. Clinical and Experimental Ophthalmology, 2017, 45, 539-547.	1.3	53
117	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurology, 2017, 74, 445.	4.5	56
118	Accelerated high-frequency repetitive transcranial magnetic stimulation enhances motor activity in rats. Neuroscience, 2017, 347, 103-110.	1.1	19
119	Immune hyperreactivity of A β 2 plaque-associated microglia in Alzheimer's disease. Neurobiology of Aging, 2017, 55, 115-122.	1.5	205
120	Subtle alterations in cerebrovascular reactivity in mild cognitive impairment detected by graph theoretical analysis and not by the standard approach. NeuroImage: Clinical, 2017, 15, 151-160.	1.4	8
121	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
122	Targeting the norepinephrinergetic system in Parkinson's disease and related disorders: The locus coeruleus story. Neurochemistry International, 2017, 102, 22-32.	1.9	95
123	Eagle syndrome: A comprehensive review. Clinical Neurology and Neurosurgery, 2017, 159, 34-38.	0.6	129
124	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 1-10.	1.2	28
125	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica, 2017, 117, 811-819.	0.5	15
126	Intracranial pressure-induced optic nerve sheath response as a predictive biomarker for optic disc edema in astronauts. Biomarkers in Medicine, 2017, 11, 1003-1008.	0.6	16

#	ARTICLE	IF	CITATIONS
127	Adapted Morris Water Maze protocol to prevent interference from confounding motor deficits on cognitive functioning. <i>Somatosensory & Motor Research</i> , 2017, 34, 172-178.	0.4	8
128	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
129	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. <i>Neurobiology of Disease</i> , 2017, 105, 235-244.	2.1	14
130	Dynamics of neutrophil gelatinase-associated lipocalin plasma and cerebrospinal fluid concentrations in older males. <i>European Journal of Clinical Investigation</i> , 2017, 47, e12853.	1.7	4
131	[P4â€“069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLYâ€“ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1284.	0.4	0
132	Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 395-405.	1.8	9
133	[P2â€“387]: EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT INVERSELY CORRELATES WITH THE PATIENT CONTRIBUTION TO CEREBRAL BLOOD FLOW NETWORK MODULARITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P777.	0.4	0
134	[P3â€“307]: RESTING STATE CONNECTIVITY RELATED TO APATHY IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1064.	0.4	0
135	[P4â€“174]: THE ASSOCIATION BETWEEN APATHY AND COGNITIVE FUNCTION IN AMNESTIC MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1329.	0.4	0
136	[P2â€“116]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P651.	0.4	0
137	The Cerebrospinal Fluid AÎ²1â€“42/AÎ²1â€“40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimerâ€™s Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 561-576.	1.2	82
138	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 309-320.	1.2	27
139	No added diagnostic value of non-phosphorylated tau fraction (p-tau _{rel}) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 49.	3.0	11
140	Optic Nerve Sheath Distention as a Protective Mechanism Against the Visual Impairment and Intracranial Pressure Syndrome in Astronauts. , 2017, 58, 4601.		19
141	â€œHypodense Holesâ€•and the Ocular Glymphatic System: Author Response: â€œBlack Holesâ€•and the Ocular Glymphatic System. , 2017, 58, 1132.		1
142	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <i>Current Alzheimer Research</i> , 2016, 13, 1145-1164.	0.7	50
143	The Glymphatic System: A New Player in Ocular Diseases?. , 2016, 57, 5426.		42
144	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 97-106.	1.2	20

#	ARTICLE	IF	CITATIONS
145	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 53-58.	1.2	13
146	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 763-776.	1.2	39
147	P1-176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, P471.	0.4	0
148	P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis. , 2016, 12, P672-P673.		0
149	P4-120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTL-GRN Mutation Carriers. <i>Alzheimer's and Dementia</i> , 2016, 12, P1058.	0.4	0
150	O4-09-03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, P354.	0.4	0
151	P1-156: Abeta Plaque-Associated Microglia Priming in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P462.	0.4	0
152	P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. , 2016, 12, P467-P468.		0
153	P4-314: Discordance Between Amyloid-PET and CSF Amyloid- β^2 for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Alzheimer's and Dementia</i> , 2016, 12, P1154.	0.4	0
154	P4-322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P1157.	0.4	0
155	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1079-1096.	1.2	33
156	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	3.9	83
157	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 105-112.	1.8	11
158	Phenotypic characteristics of Alzheimer patients carrying an <i>ABCA7</i> mutation. <i>Neurology</i> , 2016, 86, 2126-2133.	1.5	29
159	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , 2016, 629, 160-164.	1.0	34
160	Dilated Virchow-Robin spaces in primary open-angle glaucoma: a biomarker of glymphatic waste clearance dysfunction?. <i>Acta Radiologica Open</i> , 2016, 5, 205846011665363.	0.3	2
161	Clinical features of <i>TBK1</i> carriers compared with <i>C9orf72</i> , <i>GRN</i> and non-mutation carriers in a Belgian cohort. <i>Brain</i> , 2016, 139, 452-467.	3.7	86
162	Could ecosystem management provide a new framework for Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2016, 12, 65.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease. <i>International Psychogeriatrics</i> , 2015, 27, 1323-1333.	0.6	12
164	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
165	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease. , 2015, 11, P296-P297.		0
166	Serum NGAL is Associated with Distinct Plasma Amyloid- β^2 Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 733-743.	1.2	17
167	A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. <i>Journal of Neurodevelopmental Disorders</i> , 2015, 7, 3.	1.5	44
168	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. <i>Acta Neuropathologica Communications</i> , 2015, 3, 68.	2.4	13
169	A new glaucoma hypothesis: a role of glymphatic system dysfunction. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 16.	2.4	93
170	Glaucoma and the Role of Cerebrospinal Fluid Dynamics. , 2015, 56, 6630.		15
171	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , 2015, 6, 138.	1.1	44
172	Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. <i>BMJ Open</i> , 2015, 5, e007454.	0.8	141
173	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients. , 2015, 11, P626-P626.		0
174	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease. , 2015, 11, P854-P854.		0
175	Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. <i>NeuroImage</i> , 2015, 109, 151-159.	2.1	32
176	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid- β^2 Isoforms for Early and Differential Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 813-822.	1.2	82
177	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1039-1043.	1.2	15
178	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 864-869.	1.3	29
179	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	3.0	47
180	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109

#	ARTICLE	IF	CITATIONS
181	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. <i>Lancet Neurology</i> , The, 2015, 14, 814-822.	4.9	124
182	A 22â€single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid AÎ²₄₂. <i>Alzheimer's and Dementia</i> , 2015, 11, 1452-1460.	0.4	96
183	Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. <i>Physiology and Behavior</i> , 2015, 139, 397-402.	1.0	15
184	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	1.5	34
185	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. <i>MethodsX</i> , 2015, 2, 112-123.	0.7	19
186	The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimerâ€™s disease: results from a cohort study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 18.	3.0	10
187	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2015, 61, 734-743.	1.5	53
188	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. <i>Neurobiology of Disease</i> , 2015, 82, 526-539.	2.1	69
189	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. <i>Molecular Neurodegeneration</i> , 2015, 10, 30.	4.4	46
190	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , 2015, 73, 36-61.	1.1	201
191	Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort. <i>Neurology</i> , 2015, 85, 2116-2125.	1.5	151
192	A new look at glaucoma. <i>Journal of Ophthalmic and Vision Research</i> , 2015, 10, 502.	0.7	2
193	Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins. , 2014, 55, 5351.		23
194	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	0.8	57
195	Depression in Mild Cognitive Impairment is associated with Progression to Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1239-1250.	1.2	107
196	Nutritional interventions in community-dwelling Alzheimer patients with (risk of) undernutrition: a systematic review. <i>International Psychogeriatrics</i> , 2014, 26, 1445-1453.	0.6	13
197	Data modelling in corpus linguistics: How low may we go?. <i>Cortex</i> , 2014, 55, 192-201.	1.1	6
198	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. <i>Journal of Chromatography A</i> , 2014, 1353, 28-39.	1.8	36

#	ARTICLE	IF	CITATIONS
199	Risk Factors for Poststroke Depression. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 147-158.	1.2	126
200	Validation assessment of risk tools to predict outcome after thrombolytic therapy for acute ischemic stroke. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 189-193.	0.6	14
201	Sex-specific associations between Neutrophil Gelatinase-Associated Lipocalin (NGAL) and cognitive domains in late-life depression. <i>Psychoneuroendocrinology</i> , 2014, 48, 169-177.	1.3	20
202	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. <i>Journal of Immunology</i> , 2014, 193, 2147-2156.	0.4	20
203	Increased CSF β -synuclein levels in Alzheimer's disease: Correlation with tau levels. <i>Alzheimer's and Dementia</i> , 2014, 10, S290-8.	0.4	69
204	The role of low intracranial pressure in the development of glaucoma in patients with Alzheimer's disease. <i>Progress in Retinal and Eye Research</i> , 2014, 39, 107-110.	7.3	8
205	The squares test as a measure of hand function in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2014, 123, 55-60.	0.6	5
206	Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 72-84.	2.9	47
207	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2691-2700.	1.5	70
208	Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 903-909.	1.2	26
209	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 819-833.	1.2	53
210	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 871-891.	1.2	32
211	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE. , 2014, 10, P322-P323.		0
212	Senescent Changes in Cerebrospinal Fluid Circulatory Physiology and Their Role in the Pathogenesis of Normal-tension Glaucoma. <i>American Journal of Ophthalmology</i> , 2013, 156, 5-14.e2.	1.7	52
213	Neutrophil gelatinase-associated lipocalin: A novel inflammatory marker associated with late-life depression. <i>Journal of Psychosomatic Research</i> , 2013, 75, 444-450.	1.2	71
214	Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, 488-498.	0.4	37
215	Aripiprazole in the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 459-474.	0.9	46
216	Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease. <i>FASEB Journal</i> , 2012, 26, 2811-2823.	0.2	166

#	ARTICLE	IF	CITATIONS
217	Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 296-304.	1.3	16
218	Prevalence and incidence of dementia among 75-80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: The Antwerp Cognition (ANCOG) Study. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 736-745.	0.6	35
219	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
220	Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. <i>Brain Research</i> , 2011, 1378, 43-53.	1.1	37
221	Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimer's Disease. <i>Neurochemical Research</i> , 2011, 36, 1858-1862.	1.6	3
222	Comparison of extraction methods for peptidomics analysis of mouse brain tissue. <i>Journal of Neuroscience Methods</i> , 2011, 197, 231-237.	1.3	16
223	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease. , 2010, 6, S73-S74.		0
224	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1094-1099.	9.4	2,155
225	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	9.4	2,697
226	PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins. <i>Seminars in Dialysis</i> , 2009, 22, 340-345.	0.7	103
227	Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. <i>Regulatory Peptides</i> , 2009, 156, 77-82.	1.9	34
228	NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model. <i>Peptides</i> , 2009, 30, 2480-2482.	1.2	1
229	Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. <i>Neuroscience Letters</i> , 2009, 463, 93-97.	1.0	14
230	Progranulin locus deletion in frontotemporal dementia. <i>Human Mutation</i> , 2008, 29, 53-58.	1.1	85
231	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008, 29, 1143-1159.	1.5	217
232	Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memory. <i>Behavioural Brain Research</i> , 2008, 190, 147-151.	1.2	14
233	Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model.. <i>Behavioral Neuroscience</i> , 2008, 122, 491-497.	0.6	45
234	Differentiation Between Dementia and Depression Among Older Persons: Can the Difference Between Actual and Premorbid Intelligence Be Useful?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2008, 21, 242-249.	1.2	17

#	ARTICLE	IF	CITATIONS
235	Risperidone in the management of agitation and aggression associated with psychiatric disorders. <i>European Psychiatry</i> , 2006, 21, 21-28.	0.1	24
236	Dose dependent effect of APOE ϵ 4 on behavioral symptoms in frontal lobe dementia. <i>Neurobiology of Aging</i> , 2006, 27, 285-292.	1.5	64
237	Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. <i>Neurobiology of Learning and Memory</i> , 2006, 85, 164-172.	1.0	86
238	Drug Treatment: Treatment of Behavioural and Psychological Symptoms of Dementia with Neuroleptics. , 2006, , 151-162.		0
239	Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 463-467.	0.7	129
240	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 70-79.	1.3	78
241	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1028-1037.	1.3	104
242	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. <i>Neurochemistry International</i> , 2005, 46, 409-422.	1.9	39
243	Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). <i>Behavioural Brain Research</i> , 2005, 162, 233-239.	1.2	117
244	Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. <i>Clinical Neurology and Neurosurgery</i> , 2005, 107, 497-508.	0.6	88
245	Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 115-126.	1.3	171
246	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. <i>European Journal of Neuroscience</i> , 2003, 17, 388-396.	1.2	244
247	Applications of the Morris water maze in the study of learning and memory. <i>Brain Research Reviews</i> , 2001, 36, 60-90.	9.1	1,647
248	Overexpression of Arginase Alters Circulating and Tissue Amino Acids and Guanidino Compounds and Affects Neuromotor Behavior in Mice. <i>Journal of Nutrition</i> , 2001, 131, 2732-2740.	1.3	35
249	Headache As Only Symptom in Multiple Cervical Artery Dissection. <i>Headache</i> , 2001, 41, 509-511.	1.8	12
250	Risperidone in the Treatment of Behavioral and Psychological Symptoms of Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 263-269.	0.6	3
251	Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. <i>Movement Disorders</i> , 2000, 15, 1230-1237.	2.2	89
252	Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, S14-S22.	1.3	32

#	ARTICLE	IF	CITATIONS
253	Animal models of human disorders?general aspects. Neuroscience Research Communications, 2000, 26, 141-148.	0.2	12
254	Animal use in experimental neuropathology: Provisions for animal welfare and ethics. Neuroscience Research Communications, 2000, 26, 149-160.	0.2	5
255	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. Neuroscience Research Communications, 2000, 26, 193-206.	0.2	10
256	Investigating the Natural Course and Treatment of Vascular Dementia and Alzheimer's Disease: Parallel Study Populations in Two Randomized, Placebo-Controlled Trials. Annals of the New York Academy of Sciences, 2000, 903, 535-541.	1.8	26
257	Animal models of human disordersâ€”general aspects. , 2000, 26, 141.		1
258	Effects of Antiepileptic Drugs on GABA Responses and on Reduction of GABA Responses by PTZ and DMCM on Mouse Neurons in Cell Culture. Epilepsia, 1989, 30, 17-25.	2.6	39